A Phase 3 interventional study of Livalo, Ezetrol in Primary Hypercholesterolemia, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-12-01.
Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 18th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 19 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2019.
This study's enrollment of 283 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
JW Pharmaceutical has 9 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.
A Multi-center, Randomized, Double-blinded, Active-controlled, Factorial Design Phase 3 Clinical Trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pitavastatin 2mg, Ezetimibe 10mg
Drug: Livalo, Ezetrol
Pitavastatin 2mg
Drug: Livalo, Ezetrol
Pitavastatin 4mg, Ezetimibe 10mg
Drug: Livalo, Ezetrol
Pitavastatin 4mg
Drug: Livalo, Ezetrol
Drug pages: Pitavastatin · Ezetimibe
Pitavastatin+Ezetimibe Pitavastatin
Also known as: Pitavastatin, Ezetimibe
% change in LDL-C level from baseline at Week 8
change in LDL-C level
Time frame: Week 8
Change in LDL-C level from baseline at Week 4 and Week 8
change in LDL-C level
Time frame: Week 4 and Week 8
Ran from Jun 2019 to primary completion in Jul 2020, 13 months.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pitavastatin · Ezetimibe